Today, the global pharmaceutical product value chain is becoming increasingly complex and this has led to the emergence of 'multiple quality standards' for medicines. But this non-uniformity in the quality of medicine is also contingent upon both the regulatory milieu in the country of...

Fair competition law and public health law talk past each other when discussing pharmaceutical pricing and distribution. The former cannot agree on the relevant definition of consumer welfare. The latter does not fully comprehend the highly complex but inherently collective nature of...

We evaluate the impact of oral polio vaccines on the incidence of disabilities in India, focusing on polio-related disability. Polio was hyperendemic in India even as recently as the early 1990s but the country was declared wild polio virus-free in 2014. Average treatment effects on the treated...

The emergence of Covid-19 has affected all aspects of human life across the globe. Lockdowns everywhere are having dramatic social and economic consequences. No therapy has yet been approved, and vaccines are a priority potential tool to control the pandemic and its impacts. Multiple vaccines...

How harmful can government regulations and protectionism be? We provide evidence of a sizable negative impact of government interventions on population health. In 2012, the Russian government implemented a strategy to increase the affordability of pharmaceutical drugs and develop domestic...

Coronavirus Disease 2019 (COVID-19) vaccinations play a main role in the immunization campaign of nations but countries, after a certain share of people vaccinated have to cope with vaccine hesitancy and resistance in population. The goal of this study here is the detection of the max share of...

The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety. In May 2019, the European Medicines Agency (EMA) search engine showed 54 authorized biosimilars. Biosimilars...